证券代码：002864 证券简称：盘龙药业 公告编号：2025-048 特此公告。 陕西盘龙药业集团股份有限公司董事会 2025 年 10 月 09 日 1 附件：盛苑女士简历 陕西盘龙药业集团股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于近日收到中泰证券 股份有限公司（以下简称"中泰证券"）出具的《关于变更陕西盘龙药业集团股 份有限公司 2023 年向特定对象发行股票项目持续督导保荐代表人的报告》。中 泰证券作为公司 2023 年向特定对象发行股票项目的保荐机构，原指定杨圣志、 王彦忠为该项目的签字保荐代表人，持续督导期自 2023 年 10 月 26 日至 2024 年 12 月 31 日。因公司本次募集资金尚未使用完毕，中泰证券还需履行持续督导 责任。 根据中泰证券安排，其委派保荐代表人盛苑女士（简历详见附件）接替王彦 忠先生负责公司持续督导工作。本次变更后，公司 2023 年向特定对象发行股票 项目持续督导保荐代表人为杨圣志先生和盛苑女士。本次变更不影响 ...

Core Viewpoint - The company emphasizes the importance of talent development and aims to enhance its management capabilities and operational efficiency to ensure sustainable business growth and long-term value creation for investors [2]. Group 1 - The company is focused on optimizing its talent recruitment and training mechanisms in line with its strategic planning and development needs [2]. - The introduction of various professional talents is being actively considered to improve operational management levels [2]. - The company aims to strengthen its core competitiveness and operational efficiency to lay a solid foundation for long-term value growth [2].

截至2025年9月26日收盘，盘龙药业(002864)报收于29.3元，下跌0.41%，换手率2.48%，成交量1.84万 手，成交额5381.44万元。 董秘最新回复 投资者： 董秘，你好，为何不正面回答之前在互动易投资者询问的：为支持西渝高铁建设，公司拆除 了原职工宿舍，是否有货币补偿这个问题？如果有货币补偿会不会在第三季度报告里有所体现 董秘： 尊敬的投资者您好！敬请关注公司后期披露的定期报告。感谢您的关注！ 交易信息汇总资金流向 9月26日主力资金净流出6.6万元；游资资金净流出416.35万元；散户资金净流入422.95万元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 投资者： 董秘你好，公司之前因支持西渝高铁建设拆除的员工宿舍，产权证上占地面积多少平方米？ 土地价值这一块会计评估金额是多少万？后期赔偿款预计多少？预计什么时候能到账？ 董秘： 尊敬的投资者您好！敬请关注公司后期披露的定期报告。感谢您的关注！ 当日关注点 来自交易信息汇总：9月26日主力资金净流出6.6万元，散户资金净流入422.95万元。 ...

Group 1 - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao for cash, which is expected to constitute a major asset restructuring [1] - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Cloning, with a transaction value of up to 1.256 billion yuan [1] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 400-600 million USD for four VLCCs, expected delivery between late 2026 and mid-2027 [3] - Qibin Group obtained financing support of up to 90 million yuan for share repurchase [4] Group 3 - Shapuaisi's shareholder plans to reduce holdings by up to 3% of the company's total shares [5] - *ST Kaixin intends to use up to 310 million yuan for cash management in safe and liquid financial products [6] Group 4 - Junchen Technology's shareholders plan to transfer 2.5% of the company's shares due to personal funding needs [7] - Jingliang Holdings received an administrative regulatory measure from Hainan Securities Regulatory Bureau for improper revenue recognition involving 299 million yuan [7] Group 5 - Tongcheng Holdings received a cash dividend of 24.6643 million yuan from Changsha Bank [9] - Shenyang Chemical appointed Chen Liguo as the new general manager [10] Group 6 - Huaguang Huaneng signed a contract for a 160 million yuan waste heat boiler project [15] - Shuxian Valley's subsidiary completed the re-registration of a health food product [16] Group 7 - Xuanta Pharmaceutical's new specification for a diabetes treatment drug was approved [17] - Panlong Pharmaceutical's application for a pain relief gel patch was accepted by the drug regulatory authority [18] Group 8 - Zhiguang Electric's subsidiary won a procurement contract worth 164 million yuan for a storage system [19] - Chitianhua's production facility resumed operations after maintenance [20] Group 9 - Haitong Development's application for a specific A-share issuance was accepted by the Shanghai Stock Exchange, aiming to raise 210 million yuan [20] - Risheng Technology's shareholders plan to transfer 4.02% of the company's shares [33] Group 10 - Pingmei Shares' controlling shareholder plans a strategic restructuring with Henan Energy Group [35] - Shenghui Integration's controlling shareholder committed not to reduce shareholdings for 12 months [37] Group 11 - Agricultural Bank and Bank of China will no longer establish supervisory boards, with their functions transferred to the audit committees [39][40] - Dongfang Yuhong's subsidiary signed a contract for a seawater pipeline project worth 2.524 billion USD [40][41] Group 12 - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan [50] - Hanyu Pharmaceutical intends to raise up to 968 million yuan for various projects [51]

证券代码：002864 证券简称：盘龙药业 公告编号：2025-047 陕西盘龙药业集团股份有限公司 二、药品的其他相关情况 洛索洛芬钠凝胶贴膏（PLJT - 001），为治疗骨关节炎、肌肉痛、外伤后的 肿胀或疼痛的凝胶贴膏。PLJT - 001 中有效成分为洛索洛芬钠，苯丙酸类非甾体 抗炎药，具有显著的抗炎镇痛作用，尤其是镇痛作用较强。其作用机理为抑制前 列腺素合成，作用点为环化酶。洛索洛芬钠为前体药物，经皮肤吸收后，转变为 1 产品名称 洛索洛芬钠凝胶贴膏 规 格 每贴（14cm×10cm）含膏体 10g，含洛索洛芬钠 100mg（以 C15H17NaO3 计） 注册分类 化学药品 4 类 受理号 CYHS2503515 申请人 陕西盘龙药业集团股份有限公司 申请事项 境内生产药品注册上市许可 结论 根据《中华人民共和国行政许可法》第三十二条的规定，经审 查，决定予以受理。 一、药品相关情况 活性代谢物反式 - OH 体发挥作用。该凝胶贴膏具有低刺激过敏性，粘附力强不 易脱落，剂型轻薄且皮肤延展性好，可贴敷于活动关节，不影响日常活动，大幅 提升用药舒适度与便利性。 三、对公司的影响及风险提示 关于 PLJ ...

Core Viewpoint - The company, Panlong Pharmaceutical, has received a notice from the National Medical Products Administration regarding the acceptance of its application for the marketing authorization of the generic drug, Loxoprofen Sodium Gel Patch, which is intended for treating osteoarthritis, muscle pain, and swelling or pain after injuries [1] Group 1 - The product is a gel patch with significant anti-inflammatory and analgesic effects [1] - The acceptance number for the application is CYHS2503515, and it is classified as a Class 4 chemical drug [1] - The company will fulfill its information disclosure obligations in accordance with relevant regulations regarding subsequent developments [1] Group 2 - This matter is not expected to have a significant impact on the company's business operations in the short term [1]

Core Viewpoint - The company, Panlong Pharmaceutical (002864.SZ), has received a notice of acceptance for the marketing authorization application of its research product, Loxoprofen Sodium Gel Patch, from the National Medical Products Administration (NMPA) [1] Group 1: Product Information - Loxoprofen Sodium Gel Patch (PLJT-001) is designed to treat osteoarthritis, muscle pain, and swelling or pain after injuries [1] - The active ingredient, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) with significant anti-inflammatory and analgesic effects, particularly strong analgesic properties [1] - The mechanism of action involves the inhibition of prostaglandin synthesis, targeting cyclooxygenase [1] Group 2: Product Features - Loxoprofen Sodium is a prodrug that is absorbed through the skin and converted into an active metabolite, trans-OH, to exert its effects [1] - The gel patch is characterized by low irritation and allergenic potential, strong adhesion, and a lightweight formulation that allows for good skin extensibility [1] - It can be applied to active joints without affecting daily activities, significantly enhancing medication comfort and convenience [1]

Core Viewpoint - The company, Panlong Pharmaceutical (002864.SZ), has received a notice of acceptance for the marketing authorization application of its research product, Loxoprofen Sodium Gel Patch, from the National Medical Products Administration (NMPA) [1] Group 1: Product Information - Loxoprofen Sodium Gel Patch (PLJT-001) is designed to treat osteoarthritis, muscle pain, and swelling or pain following injuries [1] - The active ingredient, Loxoprofen Sodium, is a non-steroidal anti-inflammatory drug (NSAID) with significant anti-inflammatory and analgesic effects, particularly strong analgesic properties [1] - The mechanism of action involves the inhibition of prostaglandin synthesis, targeting cyclooxygenase [1] Group 2: Product Features - Loxoprofen Sodium is a prodrug that is absorbed through the skin and converted into the active metabolite trans-OH to exert its effects [1] - The gel patch is characterized by low irritation and allergenic potential, strong adhesion, and a lightweight formulation that allows for good skin extensibility [1] - It can be applied to active joints without affecting daily activities, significantly enhancing medication comfort and convenience [1]

Core Viewpoint - The company, Panlong Pharmaceutical, has received a notice from the National Medical Products Administration regarding the acceptance of its application for the marketing authorization of the generic drug, Loxoprofen Sodium Gel Patch, which is intended for the treatment of osteoarthritis, muscle pain, and swelling or pain from injuries [1] Group 1 - The Loxoprofen Sodium Gel Patch contains 100mg of Loxoprofen Sodium per patch, calculated as C15H17NaO3 [1] - Following the acceptance of the marketing authorization application, the product will undergo review and approval by the Drug Evaluation Center of the National Medical Products Administration, with completion time and approval results being uncertain [1]

证券日报网讯盘龙药业（002864）9月24日在互动平台回答投资者提问时表示，公司为妥善解决生产基 地员工的住宿需求，拟购置新楼作为公司专门的生产基地员工公寓。 ...